Table 3.
Serum CML-AGE and sRAGE in relation to risk of liver cancer, ATBC Study, 1985–2006
| Tertiles |
||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Ptrenda | Continuous b | P-value | |
| sRAGE | ||||||
| Range, pg/mL | <465.4 | 465.4 – <670.9 | ≥670.9 | |||
| Case/subcohort | 54/162 | 47/162 | 44/161 | |||
| Model 1, HR (95% CI)c | 1.00 | 0.89 (0.55, 1.43) | 0.74 (0.46, 1.18) | 0.21 | 0.84 (0.73, 0.97) | 0.02 |
| Model 2, HR (95% CI)d | 1.00 | 0.91 (0.56, 1.47) | 0.77 (0.48, 1.24) | 0.28 | 0.86 (0.75, 0.99) | 0.04 |
| CML-AGE | ||||||
| Range, ng/mL | <505.4 | 505.4 – <616.9 | ≥616.9 | |||
| Case/subcohort | 85/162 | 45/162 | 15/162 | |||
| Model 1, HR (95% CI)c | 1.00 | 0.50 (0.32, 0.79) | 0.17 (0.09, 0.32) | <0.0001 | 0.73 (0.64, 0.82) | <0.0001 |
| Model 2, HR (95% CI)d | 1.00 | 0.52 (0.33, 0.81) | 0.19 (0.10, 0.35) | <0.0001 | 0.74 (0.65, 0.84) | <0.0001 |
a
Trend test based on median values of each tertile
b
Hazard ratios for continuous sRAGE and CML-AGE were standardized to the average size of the central tertile (sRAGE, 205.5 pg/mL; CML-AGE, 111.4 ng/mL).
c
Hazard ratio, adjusted for age
d
Hazard ratio, adjusted for age, BMI, years of smoking